Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029317207> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3029317207 endingPage "4591" @default.
- W3029317207 startingPage "4591" @default.
- W3029317207 abstract "4591 Background: Cholangiocarcinoma (CCA) is the most common biliary tract malignancy with an estimated incidence of 8,000–10,000 patients/year in the US. Chemotherapy is the most common second-line treatment with reported outcomes in patients with CCA. Response rates of < 10% and median progression-free survival (PFS) times of ~3–4 months have been reported with second-line chemotherapy regimens, including FOLFOX in the ABC-06 trial. Fibroblast growth factor receptor 2 ( FGFR2) fusions occur in 13–17% of CCA and multiple targeted agents are in development for patients with FGFR2 fusions. To date, the outcome of patients with CCA and FGFR2 fusions receiving standard second-line chemotherapy is unknown. Methods: Patients with advanced CCA and FGFR2 fusions after prior treatment with gemcitabine-based chemotherapy were enrolled in a single-arm phase 2 study (NCT02150967) and received the FGFR1–3 selective TKI infigratinib (previously BGJ398) 125 mg orally qd on d1–21, cycles repeated q28 days until unacceptable toxicity, disease progression, investigator discretion, or withdrawal of consent. A retrospective analysis of a subset of patients who received infigratinib as third- or later-line treatment was performed. Investigator-assessed PFS and best overall response (BOR, per RECIST 1.1) following second-line chemotherapy (pre-infigratinib) and third-line or later-line infigratinib were calculated. Results: Of the 71 patients (44 women; median age 53 years) with FGFR2 fusions enrolled at the time of analysis (datacut 8 August 2018), 37 (52%) were included in this retrospective analysis. Median PFS with standard second-line chemotherapy was 4.63 months (95% CI 2.69–7.16) compared with 6.77 months (95% CI 3.94–7.79) for third- and later-line infigratinib. BOR for second-line chemotherapy was 5.4% (95% CI 0.7–18.2) compared with 21.6% for third- and later-line infigratinib (95% CI 9.8–38.2). Conclusions: Outcomes from second-line chemotherapy in patients with CCA and FGFR2 fusions were similar to those reported in the literature for all patients with CCA regardless of genomic status and remain dismal. Infigratinib administered as third- and later-line treatment resulted in a meaningful PFS and ORR benefit in patients with CCA and FGFR2 fusions. Clinical trial information: NCT02150967 ." @default.
- W3029317207 created "2020-06-05" @default.
- W3029317207 creator A5001797764 @default.
- W3029317207 creator A5002648450 @default.
- W3029317207 creator A5008124413 @default.
- W3029317207 creator A5011730639 @default.
- W3029317207 creator A5013744957 @default.
- W3029317207 creator A5019481117 @default.
- W3029317207 creator A5020945753 @default.
- W3029317207 creator A5035976851 @default.
- W3029317207 creator A5053703913 @default.
- W3029317207 creator A5054771911 @default.
- W3029317207 creator A5058709133 @default.
- W3029317207 creator A5072098158 @default.
- W3029317207 creator A5075688858 @default.
- W3029317207 creator A5081273660 @default.
- W3029317207 creator A5090015409 @default.
- W3029317207 date "2020-05-20" @default.
- W3029317207 modified "2023-10-15" @default.
- W3029317207 title "A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions." @default.
- W3029317207 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4591" @default.
- W3029317207 hasPublicationYear "2020" @default.
- W3029317207 type Work @default.
- W3029317207 sameAs 3029317207 @default.
- W3029317207 citedByCount "5" @default.
- W3029317207 countsByYear W30293172072021 @default.
- W3029317207 countsByYear W30293172072022 @default.
- W3029317207 crossrefType "journal-article" @default.
- W3029317207 hasAuthorship W3029317207A5001797764 @default.
- W3029317207 hasAuthorship W3029317207A5002648450 @default.
- W3029317207 hasAuthorship W3029317207A5008124413 @default.
- W3029317207 hasAuthorship W3029317207A5011730639 @default.
- W3029317207 hasAuthorship W3029317207A5013744957 @default.
- W3029317207 hasAuthorship W3029317207A5019481117 @default.
- W3029317207 hasAuthorship W3029317207A5020945753 @default.
- W3029317207 hasAuthorship W3029317207A5035976851 @default.
- W3029317207 hasAuthorship W3029317207A5053703913 @default.
- W3029317207 hasAuthorship W3029317207A5054771911 @default.
- W3029317207 hasAuthorship W3029317207A5058709133 @default.
- W3029317207 hasAuthorship W3029317207A5072098158 @default.
- W3029317207 hasAuthorship W3029317207A5075688858 @default.
- W3029317207 hasAuthorship W3029317207A5081273660 @default.
- W3029317207 hasAuthorship W3029317207A5090015409 @default.
- W3029317207 hasConcept C121608353 @default.
- W3029317207 hasConcept C126322002 @default.
- W3029317207 hasConcept C141071460 @default.
- W3029317207 hasConcept C143998085 @default.
- W3029317207 hasConcept C167135981 @default.
- W3029317207 hasConcept C2776694085 @default.
- W3029317207 hasConcept C2778260052 @default.
- W3029317207 hasConcept C2778336483 @default.
- W3029317207 hasConcept C2780258809 @default.
- W3029317207 hasConcept C2780739268 @default.
- W3029317207 hasConcept C2780962732 @default.
- W3029317207 hasConcept C526805850 @default.
- W3029317207 hasConcept C71924100 @default.
- W3029317207 hasConcept C90924648 @default.
- W3029317207 hasConceptScore W3029317207C121608353 @default.
- W3029317207 hasConceptScore W3029317207C126322002 @default.
- W3029317207 hasConceptScore W3029317207C141071460 @default.
- W3029317207 hasConceptScore W3029317207C143998085 @default.
- W3029317207 hasConceptScore W3029317207C167135981 @default.
- W3029317207 hasConceptScore W3029317207C2776694085 @default.
- W3029317207 hasConceptScore W3029317207C2778260052 @default.
- W3029317207 hasConceptScore W3029317207C2778336483 @default.
- W3029317207 hasConceptScore W3029317207C2780258809 @default.
- W3029317207 hasConceptScore W3029317207C2780739268 @default.
- W3029317207 hasConceptScore W3029317207C2780962732 @default.
- W3029317207 hasConceptScore W3029317207C526805850 @default.
- W3029317207 hasConceptScore W3029317207C71924100 @default.
- W3029317207 hasConceptScore W3029317207C90924648 @default.
- W3029317207 hasIssue "15_suppl" @default.
- W3029317207 hasLocation W30293172071 @default.
- W3029317207 hasOpenAccess W3029317207 @default.
- W3029317207 hasPrimaryLocation W30293172071 @default.
- W3029317207 hasRelatedWork W2283903823 @default.
- W3029317207 hasRelatedWork W2324427928 @default.
- W3029317207 hasRelatedWork W2362472825 @default.
- W3029317207 hasRelatedWork W2554949911 @default.
- W3029317207 hasRelatedWork W2621339296 @default.
- W3029317207 hasRelatedWork W2961286038 @default.
- W3029317207 hasRelatedWork W2980540561 @default.
- W3029317207 hasRelatedWork W2990982870 @default.
- W3029317207 hasRelatedWork W2999652398 @default.
- W3029317207 hasRelatedWork W4224218805 @default.
- W3029317207 hasVolume "38" @default.
- W3029317207 isParatext "false" @default.
- W3029317207 isRetracted "false" @default.
- W3029317207 magId "3029317207" @default.
- W3029317207 workType "article" @default.